Pharmacogenetics in clinical practice: How far have we come and where are we going?

Pharmacogenomics

Volumn 14, Issue 7, 2013, Pages 835-843

  Johnson, Julie A ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

clinical implementation; pharmacogenetics; pharmacogenomics

Indexed keywords

ABACAVIR; ALLOPURINOL; AZATHIOPRINE; CETUXIMAB; CLOPIDOGREL; CODEINE; CRIZOTINIB; DENILEUKIN DIFTITOX; EVEROLIMUS; IVACAFTOR; LAPATINIB; MARAVIROC; MERCAPTOPURINE; NEW DRUG; PANITUMUMAB; PERTUZUMAB; SIMVASTATIN; TIOGUANINE; TRASTUZUMAB; TRICYCLIC ANTIDEPRESSANT AGENT; VEMURAFENIB; WARFARIN;

ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CLINICAL PRACTICE; COLORECTAL CANCER; CYSTIC FIBROSIS; DRUG DEVELOPMENT; DRUG INDICATION; DRUG RESPONSE; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG NON SMALL CELL CANCER; METASTATIC MELANOMA; PHARMACOGENETICS; PRACTICE GUIDELINE; SOMATIC MUTATION; T CELL LYMPHOMA;

DRUG DISCOVERY; HUMANS; MUTATION; NEOPLASMS; PHARMACOGENETICS;

EID: 84877645710     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.52     Document Type: Article

References (47)

1. Collins FS, McKusick VA. Implications of the human genome project for medical science. JAMA 285(5), 540-544 (2001).
2. Ramsey BW, Davies J, Mcelvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med. 365(18), 1663-1672 (2011).
3. Rubin EH, Gilliland DG. Drug development and clinical trials -the path to an approved cancer drug. Nat. Rev. Clin. Oncol. 9(4), 215-222 (2012).
4. Asselbergs FW, Guo Y, van Iperen EP, et al. Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am. J. Hum. Genet. 91(5), 823-838 (2012).
5. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 37(2), 161-165 (2005).
6. Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 306(19), 2099-2109 (2011).
7. Do RQ, Vogel RA, Schwartz GG. PCSK9 inhibitors: potential in cardiovascular therapeutics. Curr. Cardiol. Rep. 15(3), 345 (2013).
8. Relling MV, Klein TE. CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin. Pharmacol. Ther. 89(3), 464-467 (2011).
9. Relling MV, Gardner EE, Sandborn WJ, et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Ther. 89(3), 387-391 (2011).
10. Scott SA, Sangkuhl K, Gardner EE, et al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin. Pharmacol. Ther. 90(2), 328-332 (2011).
11. Johnson JA, Gong L, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90(4), 625-629 (2011).
12. Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin. Pharmacol. Ther. 91(2), 321-326 (2012).
13. Martin MA, Klein TE, Dong BJ, Pirmohamed M, Haas DW, Kroetz DL. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin. Pharmacol. Ther. 91(4), 734-738 (2012).
14. Wilke RA, Ramsey LB, Johnson SG, et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin. Pharmacol. Ther. 92(1), 112-117 (2012).
15. Hershfield MS, Callaghan JT, Tassaneeyakul W, et al. Clinical pharmacogenetics implementation consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin. Pharmacol. Ther. 93(2), 153-158 (2013).
16. Hicks JK, Swen JJ, Thorn CF, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin. Pharmacol. Ther. 93(5), 402-408 (2013).
17. Gazzard BG, Anderson J, Babiker A, et al. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 9(8), 563-608 (2008).
18. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 308(4), 387-402 (2012).
19. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358(6), 568-579 (2008).
20. Crews KR, Cross SJ, McCormick JN, et al. Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am. J. Health Syst. Pharm. 68(2), 143-150 (2011).
21. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of gastroenterology, practice parameters committee. Am. J. Gastroenterol. 105(3), 501-523; quiz 524 (2010).
22. Pulley JM, Denny JC, Peterson JF, et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin. Pharmacol. Ther. 92(1), 87-95 (2012).
23. Johnson JA, Burkley BM, Langaee TY, Clare-Salzler MJ, Klein TE, Altman RB. Implementing personalized medicine: Development of a cost-effective custom pharmacogenetics genotyping array. Clin. Pharmacol. Ther. 92(4), 437-439 (2012).
24. Mrazek DA. Psychiatric pharmacogenomic testing in clinical practice. Dialogues Clin. Neurosci. 12(1), 69-76 (2010).
25. Roberts JD, Wells GA, Le May MR, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 379(9827), 1705-1711 (2012).
26. Scott SA. Clinical pharmacogenomics: opportunities and challenges at point of care. Clin. Pharmacol. Ther. 93(1), 33-35 (2013).
27. O'Connor SK, Ferreri SP, Michaels NM, et al. Exploratory planning and implementation of a pilot pharmacogenetic program in a community pharmacy. Pharmacogenomics 13(8), 955-962 (2012).
28. O'Donnell PH, Bush A, Spitz J, et al. The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin. Pharmacol. Ther. 92(4), 446-449 (2012).
29. Lesko LJ, Zineh I. DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA. Pharmacogenomics 11(4), 507-512 (2010).
30. Lesko LJ, Johnson JA. Academia at the crossroads: education and training in pharmacogenomics. Pers. Med. 9, 497-506 (2012).
31. Stanek EJ, Sanders CL, Taber KA, et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin. Pharmacol. Ther. 91(3), 450-458 (2012).
32. Haga SB, Burke W, Ginsburg GS, Mills R, Agans R. Primary care physicians' knowledge of and experience with pharmacogenetic testing. Clin. Genet. 82(4), 388-394 (2012).
33. Anderson JL, Adams CD, Antman EM, et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 123(18), e426-e579 (2011).
34. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 124(23), e574-e651 (2011).
35. Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non-ST- elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J. Am. Coll. Cardiol. 57(19), 1920-1959 (2011).
36. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis (9th Edition): American College of chest physicians evidence-based clinical practice guidelines. Chest 141(Suppl. 2), e152S-e184S (2012).
37. French B, Joo J, Geller NL, et al. Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials 11, 108 (2010).
38. van Schie RM, Wadelius MI, Kamali F, et al. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 10(10), 1687-1695 (2009).
39. Relling MV, Altman RB, Goetz MP, Evans WE. Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol. 11(6), 507-509 (2010).
40. Altman RB. Pharmacogenomics: "noninferiority" is sufficient for initial implementation. Clin. Pharmacol. Ther. 89(3), 348-350 (2011).
41. Binkhorst L, van Gelder T, Mathijssen RH. Individualization of tamoxifen treatment for breast carcinoma. Clin. Pharmacol. Ther. 92(4), 431-433 (2012).
42. Veenstra DL, Roth JA, Garrison LP Jr, Ramsey SD, Burke W. A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice. Genet. Med. 12(11), 686-693 (2010).
43. Khoury MJ, Coates RJ, Evans JP. Evidence-based classification of recommendations on use of genomic tests in clinical practice: dealing with insufficient evidence. Genet. Med. 12(11), 680-683 (2010).
44. Haga SB. Ethical, legal, and social challenges to applied pharmacogenetics. In: Pharmacogenomics. Applications to Patient Care. McLeod HL (Eds). American College of Clinical Pharmacy, KS, USA, 273-297 (2009).
45. US FDA Table of Pharmacogenomic Biomarkers in Drug Labels. www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm
46. The Pharmacogenomics Knowledgebase. www.PharmGKB.org
47. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents (2011). www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf